Skip to main content
. 2019 Jun 28;17(5):723–732. doi: 10.1007/s40258-019-00491-6

Fig. 3.

Fig. 3

Cost-effectiveness acceptability curve from probabilistic sensitivity analyses for adults aged ≥ 60 years (A) RZV versus no vaccination; (B): RZV versus ZVL. ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, RZV adjuvanted herpes zoster subunit vaccine, WTP willingness to pay, ZVL zoster vaccine life